clinical trial · NCT05927428
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Neurotrophic KeratitisBRM424 Ophthalmic Solution - Dose1BRM424 Ophthalmic Solution - Dose2
brief summary
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
started
Jul 31, 2024
primary completion
Aug 30, 2025
completion
Nov 30, 2025
last updated
Oct 28, 2024
official title
An Open-Label, Multi-Center, Phase 2 Dose Ranging Study of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol